Samabriva Opens New Biomanufacturing Facility

Samabriva accelerates its growth with new state of the art biomanufacturing facility.

French biotechnology company Samabriva has announced the opening of a new 1,400 m^² biomanufacturing facility in Liege, Belgium, at the heart of European’s biotech valley. This strategic investment strengthens Samabriva’s position as a leading player in the region’s thriving biomanufacturing ecosystem.

This multi-million Euros investment is designed to provide industrial scale production of high value natural molecules^* used in the manufacture of pharmaceutical products. Equipped with Samabriva’s proprietary bioreactors, which have been specifically designed to maximise production in hairy root culture, the facility will enhance efficiency and output.

This announcement represents the next step in Samabriva’s growth strategy, marking the transition to industrial production following a decade of research and development. Phase one of the facility will be operational by Q1 2025 to meet the demands of the company’s first commercial international customers.

In addition to providing advanced manufacturing, the facility will create several new jobs across bioproduction, analytics and quality assurance, contributing to global economic growth. It will also provide customers with full control over the biomanufacturing process, offering a cost effective and sustainable alternative to open field production.

^*The global botanical and plant-derivative drug market is growing rapidly (at an estimated CAGR of 8.58% between 2018 and 2026) while the recombinant protein market is expected to grow even faster (at a CAGR of 11.2% between 2021 and 2026).